Iradimed Corp (NASDAQ: IRMD)’s stock price has soared by 0.42% in relation to previous closing price of $61.54. Nevertheless, the company has seen a gain of 1.80% in its stock price over the last five trading days. zacks.com reported 2025-06-12 that LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
Is It Worth Investing in Iradimed Corp (NASDAQ: IRMD) Right Now?
Iradimed Corp (NASDAQ: IRMD) has a price-to-earnings ratio that is above its average at 39.96x. The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 1 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for IRMD is 8.01M, and at present, short sellers hold a 2.97% of that float. On July 04, 2025, the average trading volume of IRMD was 45.63K shares.
IRMD’s Market Performance
IRMD stock saw an increase of 1.80% in the past week, with a monthly gain of 3.36% and a quarterly increase of 15.30%. The volatility ratio for the week is 2.53%, and the volatility levels for the last 30 days are 2.54% for Iradimed Corp (IRMD). The simple moving average for the past 20 days is 3.16% for IRMD’s stock, with a 13.81% simple moving average for the past 200 days.
Analysts’ Opinion of IRMD
Many brokerage firms have already submitted their reports for IRMD stocks, with Lake Street repeating the rating for IRMD by listing it as a “Buy”. The predicted price for IRMD in the upcoming period, according to Lake Street is $50 based on the research report published on April 12, 2023 of the previous year 2023.
ROTH Capital gave a rating of “Buy” to IRMD, setting the target price at $30 in the report published on November 02nd of the previous year.
IRMD Trading at 9.97% from the 50-Day Moving Average
After a stumble in the market that brought IRMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.35% of loss for the given period.
Volatility was left at 2.54%, however, over the last 30 days, the volatility rate increased by 2.53%, as shares surge +1.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.64% upper at present.
During the last 5 trading sessions, IRMD rose by +1.80%, which changed the moving average for the period of 200-days by +27.50% in comparison to the 20-day moving average, which settled at $59.90. In addition, Iradimed Corp saw 42.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
GLENN JOHN, the CHIEF FINANCIAL OFFICER of Iradimed Corp, sale 2,500 shares at $54.18 during a trade that took place back on Dec 02 ’24, which means that GLENN JOHN is holding 4,383 shares at $135,449 based on the most recent closing price.
Stock Fundamentals for IRMD
Current profitability levels for the company are sitting at:
- 0.3% for the present operating margin
- 0.77% for the gross margin
The net margin for Iradimed Corp stands at 0.26%. The total capital return value is set at 0.24%. Equity return is now at value 23.81%, with 20.85% for asset returns.
Based on Iradimed Corp (IRMD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 439.6.
Currently, EBITDA for the company is 22.78 million with net debt to EBITDA at -2.21. When we switch over and look at the enterprise to sales, we see a ratio of 9.79. The receivables turnover for the company is 5.91for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.87.
Conclusion
To sum up, Iradimed Corp (IRMD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
